Webinar: Human iPSCs & High-Throughput Screening for Drug Discovery
19 October, 2021
"Fully Automated Phenotypic High-Throughput Screening in a Model of Hypertrophic Cardiomyopathy"
Oscar Bartulos, PhD
One of the pillars of drug discovery programs is the selection of a predictive preclinical model. The system, stimulus and readout should be of the highest possible clinical relevance to develop a good predictive model and help decreasing the drug attrition rate.
In this webinar we explain how patient-specific and genetically modified hiPSC-derived cells can be utilized to develop relevant assays for high-throughput phenotypic screening. We present how hiPSC-derived cardiomyocytes can be applied to perform fully automated phenotypic high-throughput screening in a model of hypertrophic cardiomyopathy.
In this webinar you will learn:
1. How to select relevant cellular models suitable for phenotypic high-throughput screening
2. Parameters to be considered for your assay development
3. Key considerations for lead selection and validation